1-甲基螺[吲哚啉-3,4-哌啶]盐酸盐 | 69584-91-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-甲基螺[吲哚啉-3,4-哌啶]盐酸盐
• 英文名称: 1'-methylspiro
• 英文别名: 1’-methyl-1,2-dihydrospiro-[indole-3,4’-piperidine]；1'-methylspiro[indoline-3,4'-piperidine]；1'-methyl-1,2-dihydro-spiro[3H-indole-3,4'-piperidine]；1'-methyl-1,2-dihydro-spiro[3H-indole-3,4'-piperdine]；1,2-dihydro-1'-methyl-spiro[3H-indole-3,4'-piperidine]；1'-methylspiro[2,3-dihydro-1H-indole-3,4'-piperidine]；N'-methyl spiro(indoline-3,4'-piperidine)；1,2-Dihydro-1'-methylspiro[3H-indole-3,4'-piperidine]；1'-methylspiro[1,2-dihydroindole-3,4'-piperidine]
• CAS: 69584-91-4
• 化学式: C₁₃H₁₈N₂
• 分子量: 202.299
• InChiKey: NPUZJRBPYOYUMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,2-Dihydro-1’-methylspiro[3h-indole-3,4’-piperidine]
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,2-Dihydro-1’-methylspiro[3h-indole-3,4’-piperidine]
CAS number: 69584-91-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18N2
Molecular weight: 202.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基螺[吲哚啉-3,4-哌啶]盐酸盐 在 palladium on activated charcoal N-甲基吗啉 、 1-氯乙基氯甲酸酯 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 26.5h， 生成 N-[1(R)-[(1,2-Dihydro-spiro[3H-indole-3,4'-piperdin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methylpropanamide
  参考文献：
  名称：

  高比活性的硫35标记的磺酰胺放射性配体的开发，可以鉴定出新的生长激素促分泌素受体。

  摘要：

  DOI：

  10.1021/jm960054c
• 作为产物：
  描述：

  4-(氨基甲基)-4-(2-氟苯基)-1-甲基哌啶 在 铜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以80%的产率得到1-甲基螺[吲哚啉-3,4-哌啶]盐酸盐
  参考文献：
  名称：

  1'-methylspiro[indoline-3,4'-piperidine] 衍生物：设计、合成、分子对接和抗肿瘤活性研究

  摘要：

  背景：螺环二氢吲哚化合物广泛存在于众多具有显着生物活性的天然产物和合成分子中。近年来，这些化合物作为有效的抗肿瘤药物在药理和化学领域受到广泛关注。 目的：在本研究中，我们重点设计和合成了新型 1'-甲基螺[二氢吲哚-3,4'-哌啶] 衍生物，并通过体外初步生物活性实验和分子对接对其进行了评估。 材料与方法：关键中间体1'-甲基螺[indoline-3,4'-哌啶]（B4）与不同取代基的苯磺酰氯在碱性条件下反应得到其衍生物（B5-B10）。我们通过 MTT 测定评估了它们对 A549、BEL-7402 和 HeLa 细胞系的抗增殖活性。我们在 Accelrys Discovery Studio 2.5.5 中执行 CDOCKER 模块以进行化合物 B5 的分子对接，并研究了化合物 B5 与三种不同靶蛋白的结合模式。 结果：结果表明化合物B4-B10对上述三种细胞系均表现出良好的抗增殖活性，其

  DOI：

  10.2174/1570180817999201117150714

文献信息

• Spiro-substituted azacycles as neurokinin antagonists
  申请人：Merck & Co., Inc.

  公开号：US06013652A1

  公开（公告）日：2000-01-11

  Disclosed are spiro-substituted azacycles of formula I are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma. In particular compounds of formula I are shown to be neurokinin antagonists.

  披露的是公式I的螺环取代的氮杂环，它们是速激肽受体拮抗剂，可用于治疗炎症性疾病、疼痛或偏头痛以及哮喘。特别是，公式I的化合物显示出是神经激肽拮抗剂。
• [EN] SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS<br/>[FR] SPIROPIPÉRIDINES UTILISABLES EN TANT QU'INHIBITEURS DE LA TRYPTASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009067202A1

  公开（公告）日：2009-05-28

  The present invention is directed to a compound of Formula (I): (I) or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.

  本发明涉及一种化合物，其化学式为（I）：（I）或其形式，其中X1、X2、X3、X4、R1、R2和R3如本文所定义，可用作色氨酸蛋白酶抑制剂。
• [EN] ALKYNYL ALCOHOLS AS KINASE INHIBITORS<br/>[FR] ALCOOLS D'ALCYNYLE UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：AMGEN INC

  公开号：WO2009158011A1

  公开（公告）日：2009-12-30

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  选定的化合物对预防和治疗炎症和炎症性疾病，如NIK介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，以及用于预防和治疗涉及炎症等疾病和其他疾病或病症的药物组合物和方法。
• Spiro-substituted azacycles as modulators of chemokine receptor activity
  申请人：Merck & Co., Inc.

  公开号：US05962462A1

  公开（公告）日：1999-10-05

  The present invention is directed to spiro-substituted azacycles of the Formula 1: ##STR1## (wherein R.sub.1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.

  本发明涉及式1所示的螺环取代的氮杂环化合物：##STR1##（其中R.sub.1，l，m，Q，W，X，Y和Z在此定义），这些化合物可用作调节化学趋化因子受体活性的调节剂。特别是，这些化合物作为化学趋化因子受体CCR-1、CCR-2、CCR-2A、CCR-2B、CCR-3、CCR-4、CCR-5、CXCR-3和/或CXCR-4的调节剂是有用的。
• [EN] SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES SUBSTITUÉS EN TANT QU'AGONISTES DE GPR ET LEURS UTILISATIONS
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015028960A1

  公开（公告）日：2015-03-05

  The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明通常涉及取代杂环衍生物（式（I）化合物），其制备方法，含有所述化合物的药物组合物，它们作为G-蛋白偶联受体（GPR）激动剂的用途，特别是作为GPR40激动剂，并且使用这些化合物治疗GPR40介导的疾病或症状，如2型糖尿病、肥胖症、血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症的方法。